Share

June 2015; 2 (3) Clinical/Scientific NotesOpen Access

Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma

Cliff W. Hampton, Dina Galperin, Enrique Alvarez, Matthew S. West
First published March 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000082
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
748

Share

This article has a correction. Please see:

Article Information

vol. 2 no. 3 e82
DOI: 
https://doi.org/10.1212/NXI.0000000000000082
PubMed: 
25798447
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 17, 2014
  • Accepted in final form January 15, 2015
  • First Published March 12, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Cliff W. Hampton, MD,
    2. Dina Galperin, MD,
    3. Enrique Alvarez, MD and
    4. Matthew S. West, MD
  1. Cliff W. Hampton, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1) Neurology, Resident & Fellow section. Editorial board member 2012-present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Dina Galperin, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Enrique Alvarez, MD and
    4. Scientific Advisory Boards:

    1. Teva neuroscience, Biogen IDEC, Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Matthew S. West, MD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, University of Colorado Denver, Aurora, CO.
  1. Correspondence to Dr. West: matthew.west{at}ucdenver.edu

Article usage

Article usage: March 2015 to October 2023

AbstractFullPdfSource
Mar 201510214726Highwire
Mar 2015020pmc
Apr 2015686411Highwire
Apr 20150205pmc
May 201540229Highwire
May 20150131pmc
Jun 2015983317Highwire
Jun 20150134pmc
Jul 20152311614Highwire
Jul 20150132pmc
Aug 201536213Highwire
Aug 20150163pmc
Sep 20151771Highwire
Sep 2015093pmc
Oct 20151171Highwire
Oct 2015081pmc
Nov 2015553Highwire
Nov 2015051pmc
Dec 2015781Highwire
Dec 2015082pmc
Jan 20161872Highwire
Jan 2016092pmc
Feb 201629123Highwire
Feb 2016082pmc
Mar 201613110Highwire
Mar 20160152pmc
Apr 20162691Highwire
Apr 2016071pmc
May 20162240Highwire
May 2016051pmc
Jun 20162754Highwire
Jun 20160164pmc
Jul 20162240Highwire
Jul 2016091pmc
Aug 20161484Highwire
Aug 2016060pmc
Sep 20161031Highwire
Sep 2016042pmc
Oct 20162057Highwire
Oct 20160163pmc
Nov 20161136Highwire
Nov 20160101pmc
Dec 2016840Highwire
Dec 20160154pmc
Jan 20171273Highwire
Jan 20170120pmc
Feb 2017620Highwire
Feb 2017050pmc
Mar 20171171Highwire
Mar 20170150pmc
Apr 2017422Highwire
Apr 201711012pmc
May 2017630Highwire
May 201701618pmc
Jun 2017310Highwire
Jun 201721718pmc
Jul 2017130Highwire
Jul 201712121pmc
Aug 2017732Highwire
Aug 201701718pmc
Sep 2017531Highwire
Sep 201732627pmc
Oct 2017573Highwire
Oct 201712424pmc
Nov 2017832Highwire
Nov 201701314pmc
Dec 2017262Highwire
Jan 20180111Highwire
Feb 20180142Highwire
Mar 20180111Highwire
Apr 20181161Highwire
Apr 201812931pmc
May 20180282Highwire
Jun 20180263Highwire
Jun 201842728pmc
Jul 20180325Highwire
Aug 20182301Highwire
Aug 201802626pmc
Sep 20180101Highwire
Oct 20180432Highwire
Nov 20181282Highwire
Dec 20180233Highwire
Jan 20191173Highwire
Feb 20193162Highwire
Mar 20192346Highwire
Apr 2019182Highwire
May 20192134Highwire
Jun 20192483Highwire
Jul 20191678Highwire
Aug 20192126Highwire
Sep 20191115Highwire
Oct 20190154Highwire
Nov 20190104Highwire
Dec 20190232Highwire
Jan 20201224Highwire
Feb 2020092Highwire
Mar 2020146Highwire
Apr 2020084Highwire
May 20200143Highwire
Jun 2020063Highwire
Jul 20201111Highwire
Aug 2020072Highwire
Sep 20201157Highwire
Oct 20201114Highwire
Nov 20200149Highwire
Dec 20200152Highwire
Jan 20212227Highwire
Feb 2021256Highwire
Mar 2021054Highwire
Apr 2021063Highwire
May 20212119Highwire
Jun 20210139Highwire
Jul 20212158Highwire
Aug 20210443Highwire
Sep 20211142Highwire
Oct 202101316Highwire
Nov 202101815Highwire
Dec 202101810Highwire
Jan 20220165Highwire
Feb 20221100Highwire
Mar 20221159Highwire
Apr 2022071Highwire
May 20221124Highwire
Jun 2022038Highwire
Jul 20221142Highwire
Aug 20220191Highwire
Sep 202212914Highwire
Oct 20221266Highwire
Nov 202206515Highwire
Dec 20221279Highwire
Jan 20230245Highwire
Feb 20230294Highwire
Mar 2023262Highwire
Apr 202301112Highwire
May 20230137Highwire
Jun 20231113Highwire
Jul 2023085Highwire
Aug 20230107Highwire
Sep 2023163Highwire
Oct 20230102Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles